Bruker Corp (BRKR)
85.77
-1.81
(-2.07%)
USD |
NASDAQ |
Apr 15, 16:00
85.75
-0.02
(-0.02%)
After-Hours: 20:00
Bruker Cash from Financing (Quarterly): -59.90M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -59.90M |
| September 30, 2023 | -92.50M |
| June 30, 2023 | -10.30M |
| March 31, 2023 | -30.70M |
| December 31, 2022 | -36.10M |
| September 30, 2022 | -82.00M |
| June 30, 2022 | -79.80M |
| March 31, 2022 | -217.40M |
| December 31, 2021 | 404.30M |
| September 30, 2021 | -2.60M |
| June 30, 2021 | -44.90M |
| March 31, 2021 | -38.10M |
| December 31, 2020 | -74.30M |
| September 30, 2020 | -225.50M |
| June 30, 2020 | -53.10M |
| March 31, 2020 | 191.30M |
| December 31, 2019 | 277.90M |
| September 30, 2019 | -19.50M |
| June 30, 2019 | 50.40M |
| March 31, 2019 | -8.80M |
| December 31, 2018 | 76.60M |
| September 30, 2018 | 14.60M |
| June 30, 2018 | -4.80M |
| March 31, 2018 | -198.80M |
| December 31, 2017 | -89.50M |
| Date | Value |
|---|---|
| September 30, 2017 | -38.90M |
| June 30, 2017 | 1.70M |
| March 31, 2017 | -32.30M |
| December 31, 2016 | 26.10M |
| September 30, 2016 | -10.50M |
| June 30, 2016 | -2.00M |
| March 31, 2016 | -41.50M |
| December 31, 2015 | -168.20M |
| September 30, 2015 | -0.10M |
| June 30, 2015 | -5.20M |
| March 31, 2015 | 4.10M |
| December 31, 2014 | 0.50M |
| September 30, 2014 | 3.00M |
| June 30, 2014 | 0.70M |
| March 31, 2014 | 2.50M |
| December 31, 2013 | 1.70M |
| September 30, 2013 | 22.10M |
| June 30, 2013 | 2.40M |
| March 31, 2013 | 0.30M |
| December 31, 2012 | 1.20M |
| September 30, 2012 | 15.70M |
| June 30, 2012 | 2.70M |
| March 31, 2012 | 14.80M |
| December 31, 2011 | -7.20M |
| September 30, 2011 | 24.50M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-225.50M
Minimum
Sep 2020
404.30M
Maximum
Dec 2021
-7.516M
Average
-38.10M
Median
Mar 2021
Cash from Financing (Quarterly) Benchmarks
| Azenta Inc | -113.15M |
| Harvard Bioscience Inc | -4.116M |
| Bionano Genomics Inc | 68.48M |
| Akoya Biosciences Inc | 11.08M |
| Singular Genomics Systems Inc | 0.072M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 205.50M |
| Cash from Investing (Quarterly) | -36.80M |
| Free Cash Flow | 243.20M |
| Free Cash Flow Per Share (Quarterly) | 1.189 |
| Free Cash Flow to Equity (Quarterly) | 112.10M |
| Free Cash Flow to Firm (Quarterly) | 175.95M |
| Free Cash Flow Yield | 1.93% |